Approach may offer new way to reverse disability in multiple sclerosis patients
A pair of topical medicines already alleviating skin conditions may prove to have another, even more compelling use: instructing stem cells in the brain to reverse damage caused by multiple sclerosis.
Led by researchers at Case Western Reserve University, a multi-institutional team used a new discovery approach to identify drugs that could activate mouse and human brain stem cells in the laboratory. The two most potent drugs—one that currently treats athlete’s foot, and the other, eczema—were capable of stimulating the regeneration of damaged brain cells and reversing paralysis when administered systemically to animal models of multiple sclerosis. The results were published online (dx.doi.org/10.1038/nature14335) Monday, April 20, in the scientific journalNature.
“We know that there are stem cells throughout the adult nervous system that are capable of repairing the damage caused by multiple sclerosis, but until now, we had no way to direct them to act,” said Paul Tesar, the Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics, and associate professor in the Department of Genetics & Genome Sciences at the Case Western Reserve School of Medicine. “Our approach was to find drugs that could catalyze the body’s own stem cells to replace the cells lost in multiple sclerosis.”
The findings mark the most promising developments to date in efforts to help the millions of people around the world who suffer from multiple sclerosis. The disease is the most common chronic neurological disorder among young adults, and results from aberrant immune cells destroying the protective coating, called myelin, around nerve cells in the brain and spinal cord.
Without myelin, neural signals cannot be transmitted properly along nerves; over time, a patient’s ability to walk, hold a cup or even see is inexorably eroded. Current multiple sclerosis therapies aim to slow further myelin destruction by the immune system, but the Case Western Reserve team used a new approach to create new myelin within the nervous system. Their work offers great promise of developing therapies that reverse disabilities caused by multiple sclerosis or similar neurological disorders.
“To replace damaged cells, much of the stem cell field has focused on direct transplantation of stem cell-derived tissues for regenerative medicine, and that approach is likely to provide enormous benefit down the road,” said Tesar, also a New York Stem Cell Foundation Robertson Investigator and member of the National Center for Regenerative Medicine. “But here we asked if we could find a faster and less invasive approach by using drugs to activate native stem cells already in the adult nervous system and direct them to form new myelin. Our ultimate goal was to enhance the body’s ability to repair itself.”
Tesar emphasized that much work remains before multiple sclerosis patients might benefit from the promising approach. Scientists still must find ways to transform the topical medications for internal use and determine their long-term efficacy and potential side effects. That said, using existing, federally approved drugs enhances the likelihood that the compounds can be made safe for human use.
The Latest on: Multiple Sclerosis
via Google News
The Latest on: Multiple Sclerosis
- Jamie-Lynn Sigler Says She’s ‘Transitioned from Feeling Like a Victim’ of Multiple Sclerosison December 12, 2019 at 2:13 pm
Jamie-Lynn Sigler has learned some “beautiful lessons” through living with multiple sclerosis. The Mob Town actress, 38, stopped by the Today show on Thursday and opened up about how her relationship ...
- Pre-Christmas promise by council to Kirkintilloch multiple sclerosis suffer has been broken, says angry local councilloron December 11, 2019 at 7:15 am
A new council home in Harestanes, which meets the needs of the multiple sclerosis sufferer who has to use a wheelchair, is still under construction - almost THREE years after the go ahead for building ...
- Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosison December 11, 2019 at 2:18 am
Neurological diseases contribute to 2% of the global burden of diseases, and are increasing in prevalence. 1 The accurate monitoring of neurological dysfunction for both clinical care and treatment ...
- Looking at the links between smoking and multiple sclerosison December 10, 2019 at 7:23 am
The risk of developing multiple sclerosis (MS) among heavy or regular smokers is about twice that of nonsmokers, according to Alberto Ascherio, professor of epidemiology and nutrition at Harvard T.H.
- Government of Alberta Supports Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) with $1 Million Investmenton December 10, 2019 at 5:00 am
TORONTO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- The Multiple Sclerosis Society of Canada, Brain Canada Foundation, Biogen Canada, and Hoffmann-La Roche Limited (Roche Canada) announced today a $1 million ...
- Multiple Sclerosis Drugs Market Size, Share | Global Market Analysis, Research Report 2026on December 9, 2019 at 10:50 pm
The global multiple sclerosis drugs market is expected to gain from the development of economical therapy to treat multiple sclerosis (MS), finds Fortune Business Insights in a report, titled ...
- Evidence uncertain whether interventions prevent falls in multiple sclerosison December 6, 2019 at 9:54 am
There is uncertainty regarding the effect of exercise and other interventions on the prevention of falls in patients with multiple sclerosis (MS), according to a review published online Nov. 28 in the ...
- Accelerated Cure Project for Multiple Sclerosis Announces Leadership Changeson December 5, 2019 at 6:00 am
WALTHAM, Mass., Dec. 5, 2019 /PRNewswire/ -- Accelerated Cure Project (ACP), a national non-profit focused on accelerating research to improve the health, healthcare and quality of life of people ...
- Deloitte and Tisch Multiple Sclerosis Research Center of New York Leverage AI, Data Science to Help Accelerate MS Research in the 'Age of With™'on December 4, 2019 at 4:00 am
NEW YORK, Dec. 4, 2019 /PRNewswire/ -- Deloitte and Tisch MS Research Center of New York (Tisch MSRCNY) are using data science, artificial intelligence (AI) and machine learning in a multiphase ...
- Multiple Sclerosis Therapeutics Market To Reach USD 25.91 Billion By 2026 | Reports And Dataon December 3, 2019 at 2:00 pm
New York, Dec 03, 2019 (GLOBE NEWSWIRE via COMTEX) -- New York, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Increased focus on drug discovery, accelerated delivery of new treatments for patients, introduction ...
via Bing News